Ibex Wealth Advisors boosted its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 59.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 165,708 shares of the company’s stock after buying an additional 61,957 shares during the period. Merck & Co., Inc. accounts for approximately 1.7% of Ibex Wealth Advisors’ portfolio, making the stock its 12th largest position. Ibex Wealth Advisors’ holdings in Merck & Co., Inc. were worth $24,079,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of MRK. Curry Webb Wealth Management LLC purchased a new position in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $29,000. Horizons Wealth Management bought a new position in shares of Merck & Co., Inc. in the 3rd quarter worth approximately $30,000. Bullseye Investment Management LLC purchased a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $27,000. Graney & King LLC lifted its stake in shares of Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after purchasing an additional 200 shares during the period. Finally, Foresight Capital Management Advisors Inc. purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at approximately $43,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.
Merck & Co., Inc. Price Performance
MRK stock opened at $147.74 on Monday. The firm has a 50 day moving average price of $146.16 and a 200-day moving average price of $128.61. Merck & Co., Inc. has a 52-week low of $91.49 and a 52-week high of $156.92. The firm has a market capitalization of $364.21 billion, a price-to-earnings ratio of 152.31, a PEG ratio of 6.77 and a beta of 0.13. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.40. The company had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.58 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 2.82 EPS for the current fiscal year.
More Merck & Co., Inc. News
Investors following MRK have been watching these news items:
- Positive Sentiment: The EMA’s CHMP recommended expanding ENFLONSIA’s use to help prevent severe RSV lower respiratory tract disease in vulnerable children up to 24 months old, including through their second RSV season. The broader eligible population could support the medicine’s commercial opportunity in Europe. Merck ENFLONSIA CHMP recommendation
- Positive Sentiment: The CHMP also recommended WELIREG plus lenvatinib for adults with advanced clear-cell renal cell carcinoma after anti-PD-1/PD-L1 treatment. This would extend WELIREG into another treatment setting and expand Merck’s oncology portfolio in Europe. Merck WELIREG CHMP recommendation
- Neutral Sentiment: Both decisions are CHMP recommendations; European Commission approval is still needed. Any financial contribution will also depend on launch timing, uptake and competition.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on MRK shares. BMO Capital Markets lifted their price target on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, August 20th. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective for the company in a report on Wednesday, August 12th. The Goldman Sachs Group increased their price objective on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, August 21st. DZ Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and set a $153.00 price objective for the company. in a research report on Tuesday, November 3rd. Finally, Wells Fargo & Company boosted their target price on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, September 4th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $155.74.
Check Out Our Latest Analysis on MRK
About Merck & Co., Inc.
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
